IDH1 mutations occurred in 6–9% of AML patients, especially in patients with normal karyotype AML (8–16%).327–333IDH1 mutations often co-occurred with normal karyotypes and NPM1 mutations,328–331,333 and were associated with wild-type CEBPA and no FLT3 mutation.331 Published results on the prognostic effects of IDH1 mutations failed to reach an agreement. This evidence concerns the gene CEBPA and acute myeloid leukemia.